CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.0320
-0.0023 (-6.71%)
At close: Apr 27, 2026
CERo Therapeutics Holdings Employees
CERo Therapeutics Holdings had 8 employees as of December 31, 2024. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$11,940,828
Market Cap
1.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 8 | -1 | -11.11% | 8 | 0 |
| Dec 31, 2023 | 9 | - | - | 8 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| LakeShore Biopharma | 573 |
| International Stem Cell | 33 |
| Evofem Biosciences | 29 |
| Lyra Therapeutics | 27 |
| Windtree Therapeutics | 14 |
CERo Therapeutics Holdings News
- 13 days ago - CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial - GlobeNewsWire
- 4 weeks ago - CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial - GlobeNewsWire
- 6 weeks ago - CERo Therapeutics Provides Shareholder Update - GlobeNewsWire
- 2 months ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 2 months ago - CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient - GlobeNewsWire
- 3 months ago - CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML - GlobeNewsWire
- 4 months ago - CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) - GlobeNewsWire
- 5 months ago - CERo Therapeutics Announces Trading on OTCQB Market - GlobeNewsWire